Re: Final Overall Survival and Safety Analyses of the Phase III PSMAfore Trial of [Lu]Lu-PSMA-617 Versus Change of Androgen Receptor Pathway Inhibitor in Taxane-Naive Patients with Metastatic Castration-Resistant Prostate Cancer.

Barata PC; Grier AL

doi:10.1016/j.eururo.2025.12.005

← 뒤로

Re: Final Overall Survival and Safety Analyses of the Phase III PSMAfore Trial of [Lu]Lu-PSMA-617 Versus Change of Androgen Receptor Pathway Inhibitor in Taxane-Naive Patients with Metastatic Castration-Resistant Prostate Cancer.

European urology 2026 Vol.89(3) p. 293-294

Barata PC, Grier AL

원문 ↗ DOI ↗ BibTeX ↓ RIS ↓

이 논문을 인용하기

BibTeX ↓ RIS ↓

APA Barata PC, Grier AL (2026). Re: Final Overall Survival and Safety Analyses of the Phase III PSMAfore Trial of [Lu]Lu-PSMA-617 Versus Change of Androgen Receptor Pathway Inhibitor in Taxane-Naive Patients with Metastatic Castration-Resistant Prostate Cancer.. European urology, 89(3), 293-294. https://doi.org/10.1016/j.eururo.2025.12.005

MLA Barata PC, et al.. "Re: Final Overall Survival and Safety Analyses of the Phase III PSMAfore Trial of [Lu]Lu-PSMA-617 Versus Change of Androgen Receptor Pathway Inhibitor in Taxane-Naive Patients with Metastatic Castration-Resistant Prostate Cancer.." European urology, vol. 89, no. 3, 2026, pp. 293-294.

PMID 41421925

DOI 10.1016/j.eururo.2025.12.005

같은 제1저자의 인용 많은 논문 (2)

Survival Outcomes of Cabazitaxel or Subsequent Androgen Receptor Pathway Inhibitor (ARPI) in Post-Docetaxel/ARPI Metastatic Castration-Resistant Prostate Cancer.
Clinical genitourinary cancer 2026
Docetaxel Rechallenge vs Cabazitaxel in Patients With Metastatic Castration-Resistant Prostate Cancer.
JAMA network open 2026